270 related articles for article (PubMed ID: 10357952)
1. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.
Albano C; Smitz J; Tournaye H; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
Hum Reprod; 1999 Jun; 14(6):1426-30. PubMed ID: 10357952
[TBL] [Abstract][Full Text] [Related]
2. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
[TBL] [Abstract][Full Text] [Related]
3. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
Tavaniotou A; Albano C; Smitz J; Devroey P
Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
[TBL] [Abstract][Full Text] [Related]
4. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
[TBL] [Abstract][Full Text] [Related]
5. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
[TBL] [Abstract][Full Text] [Related]
6. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol.
Scheffer JB; Scheffer BB; Carvalho RF; Aguiar AP; Lozano DHM; Labrosse J; Grynberg M
JBRA Assist Reprod; 2019 Aug; 23(3):239-245. PubMed ID: 30875186
[TBL] [Abstract][Full Text] [Related]
8. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study.
Felberbaum RE; Albano C; Ludwig M; Riethmüller-Winzen H; Grigat M; Devroey P; Diedrich K
Hum Reprod; 2000 May; 15(5):1015-20. PubMed ID: 10783344
[TBL] [Abstract][Full Text] [Related]
9. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix).
Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Siebert-Weigel M; Diedrich K; Van Steirteghem AC; Devroey P
Hum Reprod; 1996 Oct; 11(10):2114-8. PubMed ID: 8943511
[TBL] [Abstract][Full Text] [Related]
10. Outcome of cryopreserved pronuclear oocytes obtained after ovarian stimulation with either HMG or recFSH and the GnRH-antagonist cetrorelix.
Asimakopoulos B; Nikolettos N; Al-Hasani S
Reprod Biomed Online; 2002; 5 Suppl 1():52-6. PubMed ID: 12537782
[TBL] [Abstract][Full Text] [Related]
11. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
Gerris J; De Vits A; Joostens M; Van Royen E
Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
[TBL] [Abstract][Full Text] [Related]
12. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
13. Oocyte and embryo quality as well as pregnancy rate in intracytoplasmic sperm injection are not affected by high follicular phase serum progesterone.
Ubaldi F; Smitz J; Wisanto A; Joris H; Schiettecatte J; Derde MP; Borkham E; Van Steirteghem A; Devroey P
Hum Reprod; 1995 Dec; 10(12):3091-6. PubMed ID: 8822420
[TBL] [Abstract][Full Text] [Related]
14. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization.
Fridén BE; Nilsson L
Acta Obstet Gynecol Scand; 2005 Aug; 84(8):812-6. PubMed ID: 16026411
[TBL] [Abstract][Full Text] [Related]
15. Placental protein 14 concentrations in circulation related to hormonal parameters and reproductive outcome in women undergoing IVF/ICSI.
Westergaard LG; Yding Andersen C; Erb K; Laursen SB; Rasmussen PE; Rex S; Teisner B
Reprod Biomed Online; 2004 Jan; 8(1):91-8. PubMed ID: 14759294
[TBL] [Abstract][Full Text] [Related]
16. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix.
Albano C; Grimbizis G; Smitz J; Riethmüller-Winzen H; Reissmann T; Van Steirteghem A; Devroey P
Fertil Steril; 1998 Aug; 70(2):357-9. PubMed ID: 9696235
[TBL] [Abstract][Full Text] [Related]
17. Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial.
Mochtar MH; Hogerzeil HV; Mol BW
Hum Reprod; 1996 Aug; 11(8):1602-5. PubMed ID: 8921100
[TBL] [Abstract][Full Text] [Related]
18. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists.
Felberbaum R; Diedrich K
Hum Reprod; 1999 Sep; 14 Suppl 1():207-21. PubMed ID: 10573035
[TBL] [Abstract][Full Text] [Related]
19. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
Hwang JL; Seow KM; Lin YH; Huang LW; Hsieh BC; Tsai YL; Wu GJ; Huang SC; Chen CY; Chen PH; Tzeng CR
Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
[TBL] [Abstract][Full Text] [Related]
20. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
Wei LH; Ma WH; Tang N; Wei JH
Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
